GUCY2C
Guanylyl cyclase C
As of the edition of 20 October 2026, GUCY2C (guanylyl cyclase C, UniProt P25092) has 6 drugs tested at it and 8 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25092
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Digestive system; Cancer; Lungs and airways; Chemically induced; Immune system; Inherited and neonatal; Mental health
- Registered trials of its drugs
- 57
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Linaclotide | Marketed | Phase 4 | Ends 2029 |
| Plecanatide | Marketed | Phase 3 | Ends 2034 |
| Indusatumab vedotin | Stopped | Phase 2 | none listed |
| Dolcanatide | Went quiet | Phase 2 | none listed |
| MD-7246 | Went quiet | Phase 2 | none listed |
| PF-07062119 | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| AbbVie | Route B |
| AstraZeneca | Route B |
| Takeda | Route A |
The other 5 companies at GUCY2C
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at GUCY2C, ranked, with the facts behind eachRequest access. Nothing is shown until you do.